OBJECTIVES: With a vast number of possible treatment options for Multiple Myeloma patients, it is unclear in which combination and sequencing compounds should be used to achieve prolonged overall survival. This question cannot be timely answered with an RCT, a health economic model (1) was used to approximate for OS and adopted for a German cost setting.  METHODS: Using a combination of meta-analysis and -regression, the possible overall survival of different therapy sequences is approximated in a Markov model. Data source for this model is a systematic literature research covering 2008-2012, identifying a total of 68 studies and 11.115 patients in Multiple Myeloma. From each study treatment arm, response per therapy and therapy line was extracted. Subsequently, a regression analysis was used to specifically determine the “time to next treatment (TTNT)”. TTNT is used in our model study to reflect the positive correlation of response to therapy and disease progression, which has shown to be highly related (2-5). Using TTNT, the model can now demonstrate which sequence of therapies in 1st, 2nd and 3rdline will total to a possible OS of a patient. RESULTS: We analyzed 13 sequences from over 200 theoretical combinations, based on their German approval. Early usage of new compounds results in a prolongation of overall survival of at least 6 months, compared to the standard therapy with melphalan/prednisone (6), with minimal possible OS between 3.98 and 5.06 years. Cost data from Germany were included to amount costs of therapy for a complete sequence. For the sequences presented, costs range between 69.000 and 135.000 €. The majority of those costs accrue from drugs, not from other resources. CONCLUSIONS: An important topic of modeling approaches is to show both internal and external validity, which is both needed to validate the prognoses. The external validation is currently undertaken using data from cancer registries and non-interventional studies.